ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Not stated	2026-09-17		NCT06339658

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hospital Universitari de Bellvitge	49

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hospital de Bellvitge	L'Hospitalet de Llobregat	Spain	6

Clinical trials